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Summary
 
p52 is a subunit of nuclear factor (NF)-
 
k
 
B transcription factors, most closely related to p50.
Previously, we have shown that p52, but not p50 homodimers can form transactivating com-
plexes when associated with Bcl-3, an unusual member of the I
 
k
 
B family. To determine non-
redundant physiologic roles of p52, we generated mice deficient in p52. Null mutant mice
were impaired in their ability to generate antibodies to T-dependent antigens, consistent with
an absence of B cell follicles and follicular dendritic cell networks in secondary lymphoid or-
gans, and an inability to form germinal centers. Furthermore, the splenic marginal zone was
disrupted. These phenotypes are largely overlapping with those observed in Bcl-3 knockout
animals, but distinct from those of p50 knockouts, supporting the notion of a physiologically
relevant complex of p52 homodimers and Bcl-3. Adoptive transfer experiments further suggest
that such a complex may be critical in accessory cell functions during antigen-specific immune
reactions. Possible roles of p52 and Bcl-3 are discussed that may underlie the oncogenic poten-
tial of these proteins, as evidenced by recurrent chromosomal translocations of their genes in
lymphoid tumors.
 
T
 
he nuclear factor (NF)-
 
k
 
B transcription factors have
been implicated in the induction of numerous genes in
response to pathogen-derived or stress signals. In general,
NF-
 
k
 
B factors lie dormant in the cytoplasm of cells until ap-
propriate cellular stimulation results in their activation. The
prototypical mechanisms of activation entails rapid pro-
teolytic degradation of I
 
k
 
B proteins (including -
 
a
 
, -
 
b
 
, -
 
e
 
), a
family of closely related inhibitors of NF-
 
k
 
B, which avidly
bind to the transcription factors to retain them in the cyto-
plasm (for general reviews see references 1–4). Their signal-
induced degradation is mediated by first phosphorylation and
then ubiquitination (5, 6). Upon proteolysis-aided release
from the I
 
k
 
B inhibitors, NF-
 
k
 
B factors are subject to further
phosphorylation-mediated control to enhance their activa-
tion potential in the nucleus (7, 8).
NF-
 
k
 
B factors are homo- or heterodimeric complexes
composed of members of the NF-
 
k
 
B/Rel family of
polypeptides, which in mammalian cells includes Rel (c-Rel),
p65 (RelA), RelB, p50 (NF-
 
k
 
B1), and p52 (NF-
 
k
 
B2) (for
general reviews see references 1–4). p50 and p52 are the
two most closely related members. Although p50 is highly
ubiquitous and usually quite abundant, p52 is expressed
primarily in hematopoietic cells. Both proteins are gener-
ated from precursors by proteolytic processing; p52 derives
from p100, and p50 from p105. As precursors, both pro-
teins behave essentially like I
 
k
 
B inhibitors owing to the
presence of ankyrin repeats characteristic of I
 
k
 
B family
members. During processing, these inhibitory domains are
degraded and the resulting p50 and p52 proteins become
bona fide subunits of transactivating NF-
 
k
 
B heterodimers
with Rel, p65, or RelB. Unlike these latter proteins, how-
ever, p50 and p52 do not carry identifiable transactivation
domains and as homodimers do not transactivate by them-
selves; instead they usually function as inhibitors in various
transfection assays, competing with transactivating com-
plexes for 
 
k
 
B sites. Nevertheless, the physiologic roles of
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NF-
 
k
 
B/p52 Knockout Mice
 
p50 or p52 homodimers in the context of other transcrip-
tion factors within endogenous promoters/enhancers can
not be readily assessed.
The physiologic role of these homodimers is particularly
intriguing, not least because the homodimers appear to be
subject to regulation as well. Instead of by conventional
I
 
k
 
B proteins (-
 
a
 
, -
 
b
 
, -
 
e
 
), these homodimers are regulated
by Bcl-3, an unusual member of the I
 
k
 
B family that is not
degraded, but is induced in response to signals (9–16). In
addition, unlike the typical cytoplasmic retention of com-
plexes seen with conventional I
 
k
 
B proteins, Bcl-3, p50,
p52 homodimers are readily observed in nuclei (2, 10, 11,
14, 16, 17). As shown previously by us, a ternary complex
of DNA, p52 homodimers, and Bcl-3 can be demon-
strated, which has transactivation potential due to transacti-
vating domains on Bcl-3 (14). To what extent a similar
transactivating complex involving p50 homodimers forms
may depend on cell type and signals. In some assays, Bcl-3
rapidly disassociates p50 homodimers from DNA upon
binding, but this is not true in all cases (10–16, 18, 19). To
shed light on what may be the physiologic roles and mech-
anisms of Bcl-3 and p52, we generated knockout mice to
identify potentially unique and critical functions of these
proteins. Identification of critical functions may also help to
elucidate the oncogenic potential of both proteins, as chro-
mosomal translocations involving their respective genetic
loci have been found in some lymphoid tumors (9, 20–23).
Previously, p50 (24), I
 
k
 
B-
 
a
 
 (25, 26), Rel (27), RelB (28,
29), and p65 (30, 31) have been knocked out, and various
immunologic functions were shown to be impaired in the
mutant mice. Recently we reported that Bcl-3 knockout
mice are impaired with respect to several immunologic
parameters (32). They are defective in generation of a
switched isotype antibody response and in germinal center
formation, which parallels loss of B cell follicular structures
and follicular dendritic cell networks in secondary lym-
phoid organs. In addition they have a disrupted splenic
marginal zone and they fail to mount a protective immune
response to 
 
Toxoplasma gondii. 
 
Loss of germinal centers and
impaired antibody responses have also been reported by
others who further noted some impairment in handling of
certain bacterial infection (33). We now show that p52
knockouts share many (but not all) phenotypes with Bcl-3
knockouts, supporting the idea that p52 and Bcl-3 form a
functional, physiologically relevant complex. The data sug-
gest a role for such a complex in accessory cell function
during immune activation.
 
Materials and Methods
 
Targeted Disruption of the NF-
 
k
 
B2 Locus.
 
Two overlapping phage
clones (LC60, 
 
z
 
17 kb; and LC94, 
 
z
 
17.5 kb) spanning a 31-kb ge-
nomic region containing the NF-
 
k
 
B2 locus were isolated from a
129SV mouse genomic library (Stratagene Corp., La Jolla, CA)
and cloned into the NotI restriction site of Bluescript SK
 
2
 
 (Strat-
agene Corp.). Inserts were then mapped for restriction sites and
partially sequenced. For construction of the targeting vector, the
4.1-kb BamHI–SpeI fragment of BS-LC94 (containing exon 20
[8th ankyrin] and sequences further 3
 
9
 
) was inserted into the
BamHI site of the pPNT vector (34), immediately 3
 
9
 
 to the 
 
neo-
mycin
 
 (
 
neo
 
) gene and 5
 
9
 
 to the 
 
hsv-tk
 
 gene. Subsequently, the 1.8-
kb BamHI fragment derived from BS-LC60 was inserted into the
XhoI site (just 5
 
9
 
 of the 
 
neo
 
 gene; after filling in by Klenow reac-
tion) to generate pPNT-P52KO. In this way exons 11 to 19, en-
coding for the dimerization domain and the first seven ankyrin
repeats of p100, were replaced with the 
 
neo
 
 cassette. 50 
 
m
 
g of the
targeting construct (pPNT-P52KO) were linearized with NotI
and electroporated into 10
 
7
 
 J1, embryonic stem (ES)
 
1
 
 cells (pas-
sage 12) as detailed elsewhere (35). Positive/negative selection
was started 24 h after transfection using G418 (GIBCO BRL,
Gaithersburg, MD; 350 
 
m
 
l/ml) and ganciclovir (2 
 
m
 
M). Screen-
ing of 76 G418/ganciclovir-resistant clones revealed two cor-
rectly recombined clones, and each was used to generate inde-
pendent knockout lines (see Results).
 
Western Blot Analyses and Antibodies.
 
Whole-cell extracts were
prepared as previously described (36) and proteins were separated
by SDS-PAGE. Proteins were then blotted onto nitrocellulose
membranes by using a semidry blotter (Bio Rad Labs., Hercules,
CA), and analyzed with the enhanced chemiluminescence (ECL)
Western blotting detection system (Amersham Corp., Arlington
Heights, IL), as instructed by the manufacturer. The antibodies
used were a rabbit antipeptide antibody directed against the first
14 amino acids after the initiating methionine of the murine p50
(37), a rabbit polyclonal antibody directed against amino acids
1–398 of the human p52 (38), a rabbit antipeptide antibody to the
COOH terminus of the human p65 (39), a commercial rabbit an-
tibody recognizing amino acids 152–176 of the murine c-Rel
(Santa Cruz Biotechnology, Santa Cruz, CA) and a commercial
rabbit anti–Rel-B COOH terminal peptide antibody (amino ac-
ids 540–558, Santa Cruz Biotechnology).
 
Flow Cytometric Analysis.
 
Three-color flow cytometric (FCM)
analysis of single-cell suspensions of spleen and lymph nodes was
performed with anti-B220 PE–, anti-IgD-FITC–, anti–CD3-
FITC–, and anti-IgM-biotin–conjugated antibodies (PharMin-
gen, San Diego, CA) followed by streptavidin–Red 670 (GIBCO
BRL) as previously described (40).
 
Immunoglobulin Isotype-specific Inhibition ELISA.
 
NUNC Maxi-
sorb Immuno-plates (Thomas Scientific, Swedesboro, NY) were
coated with myeloma proteins representing various isotypes (Lit-
ton Bionetics, Inc., Charlestown, SC, or Organon Teknika,
Durham, NC) in PBS, 100 
 
m
 
l/well, 0.5 
 
m
 
g/ml, overnight, and
then blocked with 1% FCS-PBS-azide. In separate microtiter
plates, serum samples to be tested were titrated in diluent (PBS,
0.1% Tween, 0.05% BSA, 0.02% sodium azide). Goat anti–
mouse isotypes conjugated to alkaline phosphatase (Southern
Biotechnology Assoc., Birmingham, AL) were added at dilutions
predetermined by titration to be on the steep slope of the dilution
curves. These mixtures were incubated for 1.5 h and then trans-
ferred to immunoglobulin-coated ELISA plates washed with PBS-
Tween. Plates were incubated for 1 h, washed, and then incu-
bated with substrate (1 mg/ml) 
 
p
 
-nitrophenyl phosphate in 50 mM
Na-bicarbonate buffer, 1 mM MgCl
 
2
 
, pH 9.8; Sigma Chemical
Co., St. Louis, MO). Optical density was measured with Titertek
MultiScan ELISA plate reader at 414 nm.
 
1
 
Abbreviations used in this paper:
 
 DAB, 3,3
 
9
 
-diammobenzidine; ES, embry-
onic stem; FCM, flow cytometric; FDC, follicular dendritic cell; HRP,
horseradish peroxidase; LT, lymphotoxin, MM, metallophilic macrophage;
MZ, marginal zone; MZM, MZ macrophage; neo, neomycin; NF, nu-
clear factor; PNA, peanut agglutinin; RAG-1, recombination activation
gene 1; TD, T-dependent; TI, T-independent. 
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Preparation of TNP (2,4,6 trinitro-phenyl)-Conjugates and Injection
Protocols.
 
TNP-KLH or TNP-BSA (bovine serum albumin)
were prepared as previously described (41). In brief, 20 mg of
lyophilized KLH (Pierce Chemical Co., Rockford, IL) or 4.8 mg
of BSA (Pierce Chemical Co.) were dissolved in 4 ml of potas-
sium borate buffer (0.25 M, pH 9.2), and 3 or 6 mg of TNBS
(2,4,6 trinitro-benzyl sulfonic acid; Sigma Chemical Co.), respec-
tively, were added along with 16 
 
m
 
l of sodium carbonate (1 M).
The reaction was allowed to take place overnight, after which the
protein derivatives were dialyzed against PBS, pH 7.4. TNP-pro-
tein derivatives were frozen at 
 
2
 
20
 
8
 
C until use. TNP-LPS was
purchased from Sigma Chemical Co., and TNP-Ficoll was a gift
of Dr. John Inman (Laboratory of Immunology, National Insti-
tutes of Health). For the isotype-specific determination of anti-
TNP antibodies, 5–30-wk-old mice of both sexes were injected
intraperitoneally with 100 
 
m
 
g of TNP-KLH, 50 
 
m
 
g of TNP-LPS,
or 25 
 
m
 
g of TNP-Ficoll. For cryosections, mice were injected in-
traperitoreally with TNP-KHL (100 
 
m
 
g) absorbed to alum, and
spleens were collected 8 or 17 d after injection.
 
Assay for Anti–TNP-specific Antibodies.
 
Anti-TNP–specific anti-
bodies  were tested in sera of animals 24 h before and 14 d after in-
jection of the TNP conjugates by isotype-specific ELISA. 96-well
plates (Immunlon-4; Dynatech Laboratories, Inc., Vienna, VA)
were coated overnight at 4
 
8
 
C with 50 
 
m
 
g/ml of TNP-BSA in
PBS (pH 7.4) and then washed three times with PBS-Tween 20
(0.5%). Subsequently, serial dilutions of murine sera in PBS-
Tween were added to the plates and incubated overnight at 4
 
8
 
C.
After three washes in PBS-Tween, goat anti–murine IgM, IgG1,
IgG2a, IgG2b, and IgG3 conjugated to horseradish peroxidase
(HRP; 1:1,000; Southern Biotechnology Assoc.) were added, in-
cubated for 1 h at room temperature, and washed three times
with PBS-Tween. The HRP substrate ABTS (2,2
 
9
 
 azino-di [3-
ethyl-benzothiazoline sulfonate], Kirkeguard & Perry Labs., Inc.,
Gaithersburg, MD) was finally added and left at room temperature
in the dark. The reaction was stopped by addition of 1% SDS and
OD measured at 405 nm.
 
Immunoperoxidase Staining of Paraffin-embedded Tissues.
 
Spleens
were fixed in Bouin’s fixative for 24 h, fixed, and transferred into
70% ethanol. Tissues were then processed through alcohols and
xylene, embedded in paraffin, sectioned at 5 
 
m
 
m, and used for im-
munohistochemistry. Sections were stained with an anti–human
CD3 rabbit polyclonal antibody (Dako Corp., Carpinteria, CA)
or an anti–mouse CD45R/B220, biotin-conjugated rat mono-
clonal antibody (Boehringer Mannheim, Indianapolis, IN), as de-
scribed previously (32). An anti–rabbit, biotin-conjugated second-
ary antibody was subsequently used for the CD3 stain (Vector
Laboratories, Burlingame, CA). Slides were then incubated with
streptavidin-conjugated HRP and the avidin–biotin complexes
were revealed with the DAB (3,3
 
9
 
-diaminobenzidine) tetrahy-
drochloride chromogen (Sigma Chemical Co.).
 
Immunoperoxidase Staining of Frozen Sections.
 
Spleens were ex-
tracted, placed in OCT freezing medium (Miles Laboratories
Inc., Elkhart, IN), and flash frozen. 10 
 
m
 
m acetone-fixed sections
were stained as described previously (32, 42). In brief, tissue sec-
tions were rehydrated in PBS containing 0.1% BSA (fraction V,
PBS/BSA; Sigma Chemical Co.), and then blocked for 30 min
with 20% normal mouse serum and 20% goat or rabbit serum
(same species as secondary antibody) in PBS (PBS/serum). After
blocking, sections were incubated for 60 min with the primary
antibody prepared in PBS/serum, washed in PBS/BSA, and then
(except for those stained with biotinylated peanut agglutinin
[PNA] and biotinylated anti-CD35 antibody) incubated for an
additional 30 min with the biotinylated secondary antibody in
PBS/serum. After quenching endogenous peroxidase activity, tissue
sections were incubated for 30 min with streptavidin conjugated-
HRP (Vector Laboratories), washed in PBS/BSA, and the avidin–
biotin complexes were revealed with the DAB chromogen (Vector
Laboratories), according to the manufacturer’s instructions. Finally,
slides were rinsed, counterstained with methyl green (Vector Labora-
tories) and permanently mounted with Permount (Fisher Scientific,
Pittsburgh, PA). Biotinylated PNA (Pierce Chemical Co.) and the
following primary antibodies were used: biotinylated-8C12 (anti-
CD35; PharMingen), FDC-M1 (anti-FDCs; a gift of Dr. Kosco-
Vilbois, Glaxo-Wellcome Research and Development S.A.,
Switzerland, and Dr. Burton, Virginia Commonwealth University,
Richmond, VA), BM8 (anti–red pulp macrophages; BACHEM
Bioscience Inc., Philadelphia, PA), MOMA-1 (anti-metallophilic
macrophages [MMs]; BACHEM Bioscience Inc.), ERTR-9 (anti–
marginal zone macrophages [MZMs]; BACHEM Bioscience Inc.).
 
Double Staining of Frozen Sections.
 
Double immunohistochemi-
cal staining was performed on acetone-fixed cryosections. In
brief, tissue sections were rehydrated in PBS/BSA, blocked for 20
min with Dako
 
Ò
 
 Protein Block (Dako Corp.), and subsequently
incubated for 1 h with biotinylated anti-CD45RB220 antibodies
(PharMingen) followed by a 30-min incubation with alkaline
phosphatase (AP) streptavidin (Vector Laboratories). Sections
were then incubated for 1 h with HRP-conjugated PNA (Dako
Corp.) and endogenous peroxidase activity quenched with 1%
H
 
2
 
0
 
2
 
 in PBS for 15 min. Washings were as described above. Fi-
nally, AP and HRP enzymatic activities were revealed with the
Fast Red (Dako Corp.) and DAB (Vector Laboratories) chromo-
gens, respectively, and specimens mounted in aqueous mounting
medium (Dako Corp.).
 
Bone Marrow Adoptive Transfer.
 
10
 
7
 
 bone marrow cells, iso-
lated from femurs of 11-wk-old 
 
p52
 
 (
 
2
 
/
 
2
 
), (
 
1
 
/
 
2), and (1/1)
donor mice, were injected intravenously into recombination acti-
vation gene 1 (RAG-1)–deficient mice (Jackson Laboratory, Bar
Harbor, ME), which had been lethally irradiated at 900 Rads
24 h earlier. 15 wk later, adoptively transferred RAG-1–deficient
mice were injected intraperitoneally with TNP-KLH (100 mg) to
assay for serum levels of anti-TNP antibodies and bled before and
14 d after injection. For cryosections, mice were injected intra-
peritoneally with TNP-KLH (100 mg) adsorbed to alum and
spleens were collected 9 d after injection.
Results
Generation of p52/p100–deficient Mice. Mice deficient in
expression of functional p52 or p100 protein were gener-
ated by targeted gene disruption in ES cells. Homologous
recombination of the targeting vector resulted in loss of ex-
ons encoding a major part of the dimerization domain, the
nuclear translocation sequence, and the first seven ankyrin
repeats of the p52/p100 protein; these regions were re-
placed with a neo cassette (Fig. 1 A). Elimination of these
regions assures that no functional protein can be generated,
since an intact dimerization domain is essential for homo-
or heterodimerization and DNA binding, and an intact
ankyrin domain is essential for IkB-related inhibitory activ-
ities of p100 (for review see references 1–4). Two indepen-
dently derived mutant ES clones with a disrupted p52/p100
gene (Fig. 1 B, left) were microinjected into C57Bl/6 blas-
tocysts, and resulting male chimeras were bred to C57Bl/6
females to generate mice heterozygous for the mutated al-150 NF-kB/p52 Knockout Mice
lele. Matings of these animals generated p52/p100 1/2,
1/1, and 2/2 mice (Fig. 1 B, right). Both mutant ES
lines transmitted their germlines, and all results reported
here could be observed in either line.
Western analyses for expression of p52/p100 demon-
strated the absence of p52 (and p100) in the 2/2 mutant
mice, whereas expression of other members of the NF-kB
family (p50/p105, p65 [RelA], c-Rel, RelB) appeared un-
perturbed (Fig. 1 C). As expected from this, all NF-kB
complexes that did not contain p52 were readily detected
in electrophoretic mobility shift assays of unstimulated and/or
stimulated splenic cell extracts (data not shown). These data
suggest that the absence of p52 and p100 did not obviously
alter other NF-kB complexes. Mutant mice deficient in
other components of this transcription factor family also do
not show significant perturbations in the expression of the
remaining family members (24–27, 29, 30, 33).
Reduction in the B to T Cell Ratio. p52/p100–deficient
animals (hereafter referred to as p52 deficient) were born
with the expected frequency and did not exhibit obvious
macroscopic defects. However, FCM analyses indicated a
significant reduction of B2201 B cells in spleen and lymph
nodes (analysis of spleen only shown in Fig. 2 A), accom-
panied by an increase in levels of CD31 T cells (Fig. 2 A).
Therefore, the ratio of B/T was dramatically reduced in
the mutant mice. Of note, a further reduction of B cells
was observed with more advanced age (data not shown).
Among the B cells the reduction in numbers was equally
apparent regardless of whether they were positive for IgM
and/or IgD (Fig. 2 A).
Impaired Antibody Responses. The loss of B cell follicles
prompted us to investigate for potential defects in antibody
production. Although total serum levels of IgM and IgG2a
appeared essentially normal in unchallenged mutant mice,
levels of IgG1, IgG2b, and IgA were partially reduced (Fig.
2 B). (Apparent reduction in IgG3 was not statistically sig-
nificant.) We then challenged animals with the T-depen-
dent (TD) antigen TNP-KLH. Administration of this anti-
gen to mutant mice (in the absence of adjuvants) failed to
elicit significant levels of antigen-specific switched immu-
noglobulin isotypes, whereas littermate controls were able
to raise such antibodies (Fig. 3 A). The mutant mice never-
theless recognized and responded to antigen, as evidenced
by the even higher than normal antigen-specific IgM lev-
els. It is noteworthy that heterozygous animals exhibited a
partial reduction in antigen-specific switched Ig isotypes.
Together, these data suggest that p52-deficient animals are
impaired in generating full antibody responses to TD anti-
gen (in the absence of adjuvants) and that loss of one p52
allele already has a measurable effect in this assay. Consis-
tent with these results, mutant mice were also impaired in
their antibody response to a physiologically relevant chal-
lenge. Infection with influenza virus, which presents as a
TD antigen, resulted in impaired flu-specific IgG2a pro-
duction (with IgG2a being the predominant flu-specific
switched isotype produced in wild-type mice [43]; data not
shown). Therefore, p52-dependent functions are important
in this infectious model.
The mutant mice do not have absolute defects in the
ability of B cells to undergo switch recombination or to
properly respond to a TD antigen, since administration of
TNP-KLH adsorbed to alum resulted in normal or near
normal antibody responses (data not shown; the antibody
levels of wild-type controls were at least one order of mag-
nitude higher in the presence of adjuvant as compared to
without adjuvant). The presence of an adjuvant appeared to
have bypassed a critical defect in null mutant mice, a phe-
nomenon that has been observed in other mutant mice (44).
Figure 1. Targeted disruption of the p52/p100 gene. (A) The targeting
vector, a partial restriction map of the p52/p100 gene locus, and the mu-
tated allele after homologous recombination of the targeting vector are
shown. Probes used and fragments detected in Southern blots are indi-
cated. kb, kilobase pairs; tk, thymidine kinase; B, BamHI; Sm, SmaI; Sp,
SpeI; X, XbaI. (B) Southern analyses of ESs (left) and of the offsprings
from the resulting mice heterozygous for the mutated allele (PROGENY;
right). Correct homologous recombination generated a new Xba I restric-
tion fragment B (7.4 kb) in addition to the wild-type allele-derived frag-
ment A (9.4 kb), and both were detected with probe a (3.4-kb BamHI–
XbaI fragment of BS-LC94). Correct insertion of the targeting plasmid
was confirmed with SpeI digestion of genomic ES cell DNA and probe b
(1.1-kb SmaI fragment of BS-LC60) that detected fragments C and D
(wild-type allele [10.0 kb] and mutated allele [7.1 kb], respectively). A neo
probe was also used to exclude additional nonhomologous integration of
the targeting vector (data not shown). Matings of heterozygous animals
then generated p52/p100 (1/2), (1/1), and (2/2) mice that were dis-
cerned with probe g (1.8-kb BamHI fragment of LC60). This probe hy-
bridizes to the BamHI fragments E (wild-type, 1.8 kb) and F (mutant, 3.7
kb) (PROGENY). (C) Western blot analyses of spleens of p52/p100 (1/
1) and (2/2) mice are shown. Antibodies to various NF-kB family
members were used as indicated.151 Franzoso et al.
We also investigated T-independent (TI) antigens. The
response to TNP-Ficoll (TI-2) was normal in the mutant
mice, confirming that there are no absolute defects with re-
spect to the ability of B cells to undergo switching (Fig. 3
B). The response to TNP-LPS (TI-1) appeared normal as
well, except with respect to the IgG1 isotype, which was
partly reduced (Fig. 3 C).
In summary, these results are consistent with an impaired
presentation/handling of antigen by APCs and/or impaired
cellular signaling in response to TD antigen in p52-defi-
cient animals, a defect which is overcome with stronger ad-
juvant-aided stimulation.
Loss of B Cell Follicles and Germinal Centers. To charac-
terize the reduction of B cells in more detail and to search
for defects that may be consistent with problems in antigen
presentation, handling, and/or associated cell signaling, we
performed immunohistochemical analyses on paraffin-embed-
ded splenic tissue sections of null mutant mice and their lit-
termate controls (heterozygous littermates were generally
indistinguishable from wild-type littermates). B2201 B cell
follicles were severely reduced in p52-deficient animals as
compared to littermate controls (Fig. 4; the B220 marker
and the CD3 marker define B and complementary T cell
zones, respectively, within the splenic white pulp islands).
Although B cell follicular areas were depleted or absent, B
cells were still present in the marginal zone, as evidenced
by the “ring” of B2201 cells surrounding the white pulp
within the spleen. Consistent with a lack of clearly defined
Figure 2. Reduction in the B/T
cell ratio and reduced levels of
total serum antibodies in p52/
p100 ( 2 / 2 ) mice. (A) Repre-
sentative FCM analysis of sple-
nocytes from 16-wk-old p52/
p100 ( 2 / 2 ) and (1/2) mice.
IgM–Red 670 versus IgD-FITC
two-color profiles are displayed
in the top panels. Single-color
profiles depict B220-PE and
CD3-FITC staining on total
splenocytes (middle and bottom,
respectively). Numbers reflect
the percentage of positively
stained spleen cells. (B) Reduced
levels of IgG1, IgG2b, and IgA
in sera of p52/p100 (2/2) mice.
Titers of total immunoglobulin
isotypes from 7–10-wk-old
mice of each genotype are shown as indicated. IgG1, IgG2a, and IgA titers differed significantly (P ,0.002, P ,0.05, and P ,0.001) among the three
groups (1/1, 1/2, and 2/2) by one-way analysis of variance. (2/2 differed significantly from both other groups.) The reduction in levels of IgG3
observed in p52-deficient mice was not statistically significant (P 5 0.079).
Figure 3. Defective antibody response to T-dependent antigens in p52-
deficient mice. 5–30-wk-old mice of both sexes were injected intraperi-
toneally with (A) 100 mg of TNP (2,4,6 trinitro-phenyl)–KLH (TD), (B)
25 mg of TNP-Ficoll (TI-2) or (C) 50 mg of TNP-LPS (TI-1). Serum
levels of anti-TNP specific antibodies were determined by isotype-spe-
cific ELISA 14 d after injection of the TNP conjugates. Antibody levels,
expressed as OD, are shown for each genotype, as indicated. Anti-TNP
antibodies were undetectable in sera of animals before challenge (data not
shown). OD values differed significantly among the following groups of
animals by one-way analysis of variance. (A) (2/2) versus (1/1) all iso-
types tested; (2/2) versus (1/2), IgM, IgG1, IgG2b and IgG3; (1/2)
versus (1/1), IgG1, IgG2a, IgG2b. (C) (2/2) versus (1/2) and (1/1),
IgM, and IgG1. All other groups were not significantly different.152 NF-kB/p52 Knockout Mice153 Franzoso et al.
B cell follicular areas, the mutant animals also did not con-
tain germinal centers that normally form within B cell folli-
cles in response to TD antigens. Such germinal centers
could be found in littermate controls, probably in response
to environmental antigens (Fig. 4, upper right). In contrast to
p52-deficient animals, p50-deficient animals exhibited nor-
mal B cell follicles and germinal centers (Fig. 4, bottom), sug-
gesting clearly distinct roles for the two proteins (see Dis-
cussion).
The results obtained with p52-deficient mice are similar
to those obtained with Bcl-3 null mice (32). In the latter
animals, B cell follicular areas were generally diffuse and
could not be clearly defined, the switched antibody re-
sponse to influenza virus was defective, and germinal cen-
ters were largely missing. To better define the defects in
p52-deficient mice and to allow a comparison with Bcl-3–
deficient mice, we investigated the apparent loss of germi-
nal centers and the overall splenic microarchitecture in more
detail. Mice were challenged with TNP-KLH adsorbed to
alum to stimulate a vigorous response. Splenic cryosections
were stained with PNA, a marker for germinal center B
cells. Although littermate controls contained large, intensely
staining PNA positive regions within B cell follicles, the
mutant mice did not (Fig. 5 A, top). Furthermore, anti-
CD35 and FDCM1, two markers for follicular dendritic
cells (FDCs), failed to stain sections of mutant mice, but
clearly stained the FDC-containing B cell follicular region
in littermate controls (Fig. 5 A, middle and bottom). Since
FDCs are a hallmark of the light zone of germinal centers,
these data demonstrate that p52-deficient mice not only lack
defined B cell follicular areas, but that they are also totally
unable to form germinal centers. Although small, weakly
staining PNA positive foci were sometimes observed, they
were located within the T cell area, as shown by double stain-
ing with PNA and anti-B220 antibodies (Fig. 5 B). It is
possible that these cells represent pre–germinal center B
cells that are no longer able to or are otherwise prevented
from forming germinal centers. It remains to be explored if
such cells could be responsible for the adjuvant-aided anti-
body response of mutant mice to TD antigens.
Adoptive Transfer. The above data indicate that p52-defi-
cient animals are defective in some aspects of antigen-spe-
cific activation of B cells, either in the presentation/han-
dling of antigen by accessory cells, or in the signaling between
accessory cells and B and T cells, or both. To better define
those cells of mutant mice that contain biologically relevant
defects, we adoptively transferred bone marrow of p52 null
mutant mice into irradiated RAG-1–deficient animals, which
lack both B and T cells (45). Thereafter, we challenged these
mice with TNP-KLH adsorbed to alum and we investi-
gated their ability to form germinal centers. As seen in Fig.
6, simultaneous staining with anti-B220 antibodies and
PNA now revealed the presence of germinal center PNA1 B
cells within B2201 follicular areas. Furthermore, challenge
of adoptively transferred animals with TNP-KLH in the
absence of alum now elicited a switched antibody response,
albeit a weaker one than that seen with transfer of wild-
type bone marrow (data not shown). Therefore, the inabil-
ity to form germinal centers and the impaired switched anti-
body response to a TD antigen in p52-deficient mice can-
not be explained by absolute defects within the p52-deficient
B or T cells; in RAG-1 mice these p52-lacking lympho-
cytes were capable of participating in germinal center reac-
tions and generation of switched antibodies in the absence
of adjuvants. Adoptively transferred Bcl-3–deficient lym-
phocytes could also participate in germinal center reactions
(Franzoso, G., L. Poljak, and U. Siebenlist, unpublished
observations).
Impaired Marginal Zone Architecture. To further investi-
gate for possible similarities with Bcl-3–deficient mice, we
looked at the splenic marginal zone surrounding the white
pulp by staining splenic cryosections of p52–deficient mice
with markers for local macrophage populations. MMs con-
stitute a subset of macrophages that reside in the inner ring
of the marginal zone (MZ) and they can be detected with
the MOMA-1 antibody (46). When sections of mutant mice
were stained with MOMA-1, no MMs were detected,
whereas the MZ of littermate controls was clearly stained
(Fig. 7, bottom). This is reminiscent of the data obtained
with Bcl-3–deficient animals, where MMs are severely re-
duced in numbers (32). In contrast, MZMs, which are lo-
cated in the outer ring of MZs and which are detected with
the ERTR-9 marker (46), were readily observed in p52–
deficient animals (Fig. 7, middle), but are lacking in Bcl-3–
deficient animals (32). Nevertheless, some p52 null mutant
mice exhibited reduced numbers of these cells as well (not
shown).
The MZ is considered critical to the control of cell traf-
ficking into the white pulp (47). Consistent with an appar-
ently impaired MZ architecture and thus impaired traffic
control in mutant mice, the white pulp of these animals ap-
peared to have been infiltrated with macrophage subpopu-
lations that are normally completely excluded (Fig. 7, top,
BM8). The same phenomenon has been observed in Bcl-
3–deficient mice (32). Together, the data further document
the close similarities, but also some differences between
p52– and Bcl-3–deficient mice, implying that these pro-
teins share many, but not all functions.
Infection with T. gondii. p52-deficient animals were infected
with T. gondii, an infectious model for T cell dependent
immunity. We previously demonstrated that Bcl-3–defi-
cient animals succumb to infection with an avirulent T.
gondii strain within 3–5 wk of parasite exposure, and that
this defect is related to an inability to mount an adequate
host response; in particular, T helper 1 cells appeared not to
be primed in vivo, resulting in absence of IFN-g produc-
Figure 4. Germinal centers and B cell follicles are absent in spleens of p52 (2/2) mice, but are present in p50 (2/2) mice. Analyses of spleens taken
from an unchallenged, 21-wk-old p52/p10 (2/2) mouse, a (1/2) littermate control (top and middle, respectively), and an unchallenged 15-wk-old p50/
p105 (2/2) mouse (bottom). Bouin-fixed, paraffin-embedded sections were processed with anti-CD3 or anti-B220 antibodies, as indicated.154 NF-kB/p52 Knockout Mice155 Franzoso et al.
tion from these cells (32). By contrast, p52-deficient ani-
mals displayed a protracted pattern of mortality with some
animals succumbing as early as 1 wk after infection and
others surviving beyond the 16-wk period of observation
(Fig. 8). The basis for this partial impairment is unknown.
The data suggest that Bcl-3 and p52 serve somewhat dis-
tinct roles in determining resistance to T. gondii.
Discussion
We have demonstrated that p52–deficient animals (a)
have reduced numbers of B cells, consistent with a loss of B
cell follicles within their spleens and lymph nodes, (b) are
unable to form germinal centers and are impaired in anti-
body responses to TD antigens, (c) lack follicular dendritic
cell networks, (d) lack MMs in the splenic MZ and are im-
paired in exclusion of cells from the white pulp. We have
also demonstrated that the inability to generate germinal
centers does not track with lymphocytes, as adoptively trans-
ferred p52-deficient lymphocytes can form germinal cen-
ters in RAG-1–deficient mice. Together, these data reveal
a defect in p52 null mutant mice in select aspects of anti-
gen-dependent activation of lymphocytes, and they impli-
cate accessory cells as primary effectors of unique and critical
functions for p52 in wild-type animals (especially in follicu-
lar dendritic cells; see below).
Many defects observed in p52 null mice are very similar
to those observed in Bcl-3–deficient animals (32). This
supports the notion that a ternary complex of DNA-bind-
ing p52 homodimers and Bcl-3 (14) may regulate expres-
sion of some critical genes. Nevertheless, these two pro-
teins are likely to have separate functions as well. Mice
deficient in p52 not only lack p52 homodimers, they also
lack the p100 precursor and any heterodimeric complexes
containing p52. If these latter complexes have critical, non-
redundant functions, we would expect to see defects inde-
pendent of Bcl-3. Similarly, Bcl-3 may have critical, non-
redundant functions, independent of p52 (see below). As
shown here, Bcl-3 and p52 knockouts differ somewhat with
respect to resistance to infection with T. gondii and loss of
MZMs and MMs (32).
In contrast to mice deficient in Bcl-3 or p52, mice lack-
ing p50 form apparently normal B cell follicles, normal ger-
minal centers, normal follicular dendritic networks, and ex-
hibit no loss of macrophages of the marginal zone (Fig. 4,
and Franzoso, G., L. Poljak, and U. Siebenlist, unpublished
observations; reference 33). Therefore, the data have re-
vealed several specific biologic functions that depend on
both Bcl-3 and p52, but not on p50, despite the fact that
p50 is quite homologous to p52, and despite the fact that
Bcl-3 is known to interact with p50 homodimers (although
this interaction may differ from that with p52 homodimers;
see Introduction) (10–13, 15, 16). Clear biologic contexts
in which a complex between p50 homodimers and Bcl-3 is
uniquely critical have yet to be described, although mice
deficient in p50 or in Bcl-3 have been reported as impaired
in their overall ability to contain certain bacterial infections
(24, 32, 33). It remains possible, of course, that p50 ho-
modimers and Bcl-3 have antagonistic activities (see Intro-
duction).
Given the present data, it appears that a complex of p52
and Bcl-3 may be particularly critical for some accessory
cell functions during antigen-dependent stimulation of lym-
phocytes. Adoptively transferred lymphocytes lacking p52
(or lacking Bcl-3) can form germinal centers in RAG-1–
deficient mice and generate at least some T-dependent an-
tibody responses, even in the absence of adjuvants. This
implies that the primary defects with respect to these bio-
logic processes do not reside within the mature, p52–defi-
cient B or T cell lineages, which implicates accessory cells.
In this regard, the apparent loss of follicular dendritic cell
networks in both p52– and Bcl-3–deficient mice is particu-
larly noteworthy and could account for the impairment in
B cell follicular structure and the lack of germinal center
formation (Figs. 4 and 5; reference 32). On the other hand,
FDCs may not always be absolutely necessary for germinal
Figure 5. Absence of germinal centers and dendritic cell networks in spleens of challenged p52/p100 (2/2) mice. 13–15-wk-old p52/p100 (2/2),
(1/2), and (1/2) control mice were challenged by intraperitoneal injection of 100 mg of alum-adsorbed TNP-KLH. Frozen sections of spleens were
obtained 8 or 17 d after injection and stained (A) with PNA, anti-CD35(CR1), or FDC-M1 antibodies and (B) with PNA (purple) and anti-B220 anti-
bodies (pink), as indicated. Stained cryosections from representative pairs of littermates are shown.
Figure 6. Adoptively transferred p52-deficient lymphocytes support for-
mation of germinal centers in RAG–1-deficient mice. Lethally irradiated
RAG-1–deficient mice were injected with bone marrow cells isolated
from 11-wk-old p52 (2/2), (1/2), and (1/1) donor mice, and 15 wk
later challenged intraperitoneally with TNP-KLH (100 mg) adsorbed to
alum. Splenic cryosections were obtained 9 d after challenge and stained
with PNA (purple) and anti-B220 antibodies (pink). Stained cryosections
from a representative p52/p100 (2/2) marrow transferred animal is shown.156 NF-kB/p52 Knockout Mice157 Franzoso et al.
center formation (48). It remains to be shown if defects lie
within FDCs themselves or if they lie elsewhere, for exam-
ple, in some other long-lived non–T, non–B cells or in
nonhematopoietic cells. Previous data suggest high expres-
sion of p52 in FDCs (49), supporting the notion that this
protein has important functions within FDCs. It is possible
that p52 and Bcl-3 are needed for the development/differ-
entiation of these cells, acting directly or indirectly, just like
RelB is required for formation of mature interdigitating
dendritic cells (IDCs; references 28, 29); (IDCs are present
in both p52 and Bcl-3 knockout mice [Franzoso, G. and
U. Siebenlist, unpublished observations].) It is worth not-
ing also that the absence of p52 or Bcl-3 may well have di-
rect effects in more than one cell type. In any case, a corre-
lation between the failure to form FDC networks and
impaired antibody response has also been noted in lympho-
toxin (LT)a–deficient mice (50).
Adjuvant-aided presentation of antigen in p52 knockout
mice appears to be able to compensate for the dramatic fail-
ure to respond to TD antigens without adjuvants. Al-
though even then, proper germinal centers were still not
observed. (Antibody production in the absence of germinal
centers has been previously observed in LTa knockout
mice [51].) This indicates a largely normal behavior of mu-
tant lymphocytes once they are stimulated, implying that
defects in the mutant mice must lie in other cell types.
Strong adjuvant-aided antigenic stimulation may be associ-
ated with inflammation and thus production of cytokines
in the mutant mice, which may overcome what is other-
wise a defective priming of lymphocytes by accessory cells.
Which genes could be the unique targets of p52 and Bcl-3?
Such genes must be regulated, at least in part, by nonredun-
dant functions of these proteins. One clue may come from
mutant mice that present with partially related phenotypes.
For example, mice deficient in TNF-a, TNF receptor I,
LTa, or LTb display disrupted lymphoid microarchitecture
including lack of germinal centers and FDC networks (52–
56). An absence of germinal centers has also been noted in
mutant mice deficient in various proteins known to be in-
volved in costimulatory signaling during antigen presenta-
tion, such as CD40 and CD40 ligand, but these mice have
apparently normal lymphoid architecture (47, 57–59). All
of these null mutant mice do have additional phenotypes
that are not shared with p52– and Bcl-3–deficient mice. Still,
it is quite likely that specific aspects of the signaling cascades
that occur during in vivo antigenic stimulations are impaired
in p52– or Bcl-3–deficient mice and/or that the specific in
vivo microenvironments are disrupted that are needed to set
up proper antigen-stimulated signaling cascades between
cells. It remains to be shown if p52 and Bcl-3 lie on some
of the same signaling pathways disrupted in the knockouts
discussed above. In this regard, it is important to note that
NF-kB complexes control, as well as are controlled by var-
ious members of the TNF ligand and TNF receptor fami-
lies (2, 4, 60, 61), allowing for multiple ways in which
these particular molecules could be functionally connected.
Identification of molecular targets involved will be essential
to understanding how these proteins regulate gene expres-
sion and how antigen priming is accomplished in vivo.
Since both p52 and Bcl-3 have been found to be associ-
ated with recurrent translocations (9, 20–23), it is notewor-
thy that an absence of either protein leads to losses in B cell
numbers, in particular with age and with immune chal-
lenges. This suggests that p52 and Bcl-3 normally help to
maintain B cells. When overexpressed and/or inappropri-
ately expressed, these properties of p52 and Bcl-3 may con-
tribute to tumor formation.
Figure 7. Altered MZ microarchitecture in spleens of p52/p100 (2/2) mice. Splenic cryosections were derived from the same group of p52/p100 (2/
2), (1/2), and (1/1) mice that were used for Fig. 5. Sections were stained with monoclonal antibodies specific to red pulp macrophages (RPM; BM8),
MMs (MOMA-1) or MZMs; (ERTR-9), as indicated. Similar results were obtained with spleens from unchallenged animals (data not shown).
Figure 8. p52/p100 ( 2 / 2 )
mice are more susceptible to T.
gondii infection. p52/p100 (2/2)
mice and (1/2) and (1/1) lit-
termates were injected intraperito-
neally with z20 cysts of the aviru-
lent T. gondii strain ME49 (initially
provided by Dr. J. Remington,
Palo Alto Research Foundation,
Palo Alto, CA), as detailed previ-
ously (62). 10–23-wk-old mice
of both sexes were used as follows: 17 (2/2), 15 (1/2), and 4 (1/1)
animals. Data are shown as percent survival calculated from two indepen-
dent experiments.
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